BioVie Inc. is a clinical stage company pursuing the discovery, development, and commercialization of innovative drug therapies in liver disease. The Company is focused on commercializing BIV , a novel approach to the treatment of ascites due to chronic liver cirrhosis. Liver cirrhosis claims approximately , American lives each year. The FDA has never approved any drugs specifically for treating ascites and there is a substantial unmet medical need. The Company s new drug candidate BIV has Orphan Drug designation and is patented in the US. In early , the Company s investigational new drug IND application was cleared by the FDA to begin a Phase a clinical trial. This patient trial is being conducted at the McGuire Research Institute in Richmond, VA. As of year end , refractory ascites patients had been treated with BIV .
Quote | BioVie Inc. (OTCMKTS:BIVI)
Last: | $9.99 |
---|---|
Change Percent: | -20.08% |
Open: | $10.5 |
Close: | $9.99 |
High: | $10.99 |
Low: | $9.7 |
Volume: | 553,497 |
Last Trade Date Time: | 09/18/2020 04:53:41 pm |
News | BioVie Inc. (OTCMKTS:BIVI)
ORLANDO, FL / ACCESSWIRE / July 5, 2024 / RedChip Companies will air interviews with BioVie, Inc. (Nasdaq:BIVI) and bioAffinity Technologies, Inc. (Nasdaq:BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 6, at 7 p.m. Eastern Ti...
SUNRISE-PD to evaluate the effect of bezisterim (NE3107) on motor and non-motor symptoms in ~60 patients with Parkinson’s disease who are naïve to carbidopa/levodopa Additional presentation at congress highlighted data from earlier Phase 2a trial of bezisterim in Parkinson...
Message Board Posts | BioVie Inc. (OTCMKTS:BIVI)
Subject | By | Source | When |
---|---|---|---|
$BIVI are we finally gonna see some action | TheFinalCD | investorshub | 06/24/2023 6:10:56 PM |
$BIVI Price trading | duderaja | investorshub | 06/23/2023 1:14:59 PM |
Good read | akamaii | investorshub | 06/21/2023 1:02:47 AM |
MomentumIts trading | 02opida | investorshub | 06/18/2023 8:30:10 PM |
The now | subslover | investorshub | 06/17/2023 1:17:54 AM |
News, Short Squeeze, Breakout and More Instantly...
ORLANDO, FL / ACCESSWIRE / July 5, 2024 / RedChip Companies will air interviews with BioVie, Inc. (Nasdaq:BIVI) and bioAffinity Technologies, Inc. (Nasdaq:BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 6, at 7 p.m. Eastern Ti...
SUNRISE-PD to evaluate the effect of bezisterim (NE3107) on motor and non-motor symptoms in ~60 patients with Parkinson’s disease who are naïve to carbidopa/levodopa Additional presentation at congress highlighted data from earlier Phase 2a trial of bezisterim in Parkinson...
ORLANDO, FL / ACCESSWIRE / June 21, 2024 / RedChip Companies will air interviews with BioVie, Inc. (Nasdaq:BIVI) and Mobilicom Ltd. (Nasdaq:MOB) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, June 22, at 7 p.m. Eastern Time (ET). Bloomb...